Our Experience of Using Lenalidomide, Bortezomib and Dexamethasone (RVD) Therapy in Patients with Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Pogosyan, Gayane [1 ]
机构：
[1] Fed Almazov Med Res Ctr, Dept Hematol, St Petersburg, Russia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-214
引用
收藏
页码：S340 / S341
页数：2
相关论文
共 50 条
  • [21] SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN VERY ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Castelli, R.
    Pantaleo, G.
    Gallipoli, P.
    Arquati, M.
    Wu, M. A.
    Deliliers, G. Lambertenghi
    Cicardi, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 740 - 740
  • [22] Bortezomib, liposomal doxorubicin and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma
    Falcone, A.
    Sanpaolo, G.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Scalzulli, F.
    Cascavilla, N.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 147 - 148
  • [23] Total costs of therapy with lenalidomide or bortezomib in relapsed/refractory multiple myeloma (rrMM).
    Borrello, Ivan
    Binder, Gary
    Khan, Zeba M.
    Pashos, Chris L.
    Durie, Brian G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132
  • [25] Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Dabkara, Deepak
    Bajpai, Jyoti
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 10 - 13
  • [26] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Ri, M.
    Suzuki, K.
    Chou, T.
    Sugiura, I.
    Takezako, N.
    Sunami, K.
    Ishida, T.
    Izumi, T.
    Ozaki, S.
    Iida, S.
    [J]. HAEMATOLOGICA, 2016, 101 : 787 - 788
  • [27] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    Siegel, D. S.
    Richardson, P.
    Dimopoulos, M.
    Moreau, P.
    Mitsiades, C.
    Weber, D.
    Houp, J.
    Gause, C.
    Vuocolo, S.
    Eid, J.
    Graef, T.
    Anderson, K. C.
    [J]. BLOOD CANCER JOURNAL, 2014, 4 : e182 - e182
  • [28] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    [J]. Blood Cancer Journal, 2014, 4 : e182 - e182
  • [29] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 374 - 375
  • [30] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Munshi, Nikhil C.
    Mitsiades, Constantine
    Richardson, Paul G.
    Anderson, Kenneth C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 374 - 375
12345